Guyon A, Rousseau J, Bégin F-G et al (2020) Base editing strategy allows insertion of the A673T mutation in APP gene to prevent the development of Alzheimer’s disease. Mol Therapy-Nucleic Acids 4:24:253–263

Google Scholar 

Al-Kuraishy HM, Sulaiman GM, Mohammed HA, Saad HM, Al-Gareeb AI, Albuhadily AK (2025) Targeting the JAK/STAT3/SOCS signaling pathway in Alzheimer’s disease. Inflammopharmacology 33(6):2951–2962

Article  PubMed  Google Scholar 

Yoon BH, Kim J, Sengupta S, Park CJ, Ko M, Kang JH, Ko YT, Kim Y, Lim SM, Bae Y, Choi M (2025) Targeted autophagic clearance of Tau protects against Alzheimer’s disease through amelioration of Tau-mediated lysosomal stress. Theranostics 15(17):9240

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roy ER, Cao W (2025) Advancing Alzheimer’s research by improving disease modeling of secondary tauopathy. npj Dement 1(1):38

Article  PubMed  PubMed Central  Google Scholar 

Yiannopoulou KG, Anastasiou AI, Zachariou V, Pelidou S (2019) Reasons for Failed trials of Disease-modifying Treatments for Alzheimer Disease and their Contribution in Recent Research. Biomedicines 9(4):97

Article  Google Scholar 

Sheng J, Zhang S, Wu L et al (2022) Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer’s disease. Front Aging Neurosci 14. https://doi.org/10.3389/fnagi.2022.1019187

Al-Kuraishy HM, Alexiou A, Papadakis M, Elhussieny O, Saad HM, Batiha GE (2023) New insights on the potential effect of vinpocetine in Parkinson’s disease: one of the neglected warden and baffling topics. Metab Brain Dis 38(6):1831–1840

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tropea MR, Gulisano W, Vacanti V et al (2022) Nitric oxide/cGMP/CREB pathway and amyloid-beta crosstalk: From physiology to Alzheimer’s disease. Free Radic Biol Med 193:657–668. https://doi.org/10.1016/j.freeradbiomed.2022.11.022

Article  CAS  PubMed  Google Scholar 

Ahmad N, Lesa KN, Sudarmanto A, Fakhrudin N, Ikawati Z (2022) The role of Phosphodiesterase-1 and its natural product inhibitors in Alzheimer’s disease: A review. Front Pharmacol 13:1070677

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Kuraishy HM, Al-Gareeb AI, Naji MT, Al-Mamorry F (2020) Role of vinpocetine in ischemic stroke and poststroke outcomes: A critical review. Brain Circulation 6(1):1–0

Article  PubMed  PubMed Central  Google Scholar 

Al-Kuraishy H, Al-Windy S, Algareeb AI (2012) The Effects of Vinpocetine on the Psychomotor Performances: Randomized clinical trial, single blind random clinical study. Al-Nahrain J Sci 15(3):129–133

Google Scholar 

Ma Z, Liu X, Xie X, Fang Y, Jiang D, Zhao C, Li P, Fu Y, Ye L, Gao Y, Wu S (2025) Vinpocetine-mediated multidimensional active targeted delivery across the blood-brain barrier. J Controlled Release 382:113768

Article  CAS  Google Scholar 

Panda PK, Ramachandran A, Panda P, Sharawat IK (2022) Safety and efficacy of vinpocetine as a neuroprotective agent in acute ischemic stroke: a systematic review and meta-analysis. Neurocrit Care 37(1):314–325

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hou B, Li D, Wang D et al (2023) Neuroprotective Effects of Vinpocetine Against Ischemia-Reperfusion Injury Via Inhibiting NLRP3 Inflammasome Signaling Pathway. Neuroscience 526:74–84. https://doi.org/10.1016/j.neuroscience.2023.05.021

Article  CAS  PubMed  Google Scholar 

Bönöczk P, Gulyás B, Adam-Vizi V et al (2000) Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull 53:245–254. https://doi.org/10.1016/s0361-9230(00)00354-3

Article  PubMed  Google Scholar 

Zhao M, Hou S, Feng L, Shen P, Nan D, Zhang Y, Wang F, Ma D, Feng J (2020) Vinpocetine protects against cerebral ischemia-reperfusion injury by targeting astrocytic connexin43 via the PI3K/AKT signaling pathway. Front NeuroSci 14:223

Article  PubMed  PubMed Central  Google Scholar 

Alkuraishy HM, Al-Gareeb AI, Albuhadilly AK (2014) Vinpocetine and pyritinol: a new model for blood rheological modulation in cerebrovascular disorders—a randomized controlled clinical study. Biomed Res Int 2014(1):324307

PubMed  PubMed Central  Google Scholar 

Panda PK, Ramachandran A, Panda P, Sharawat IK (2022) Safety and Efficacy of Vinpocetine as a Neuroprotective Agent in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Neurocrit Care 37:314–325. https://doi.org/10.1007/s12028-022-01499-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nadeem RI, Ahmed HI, El-Sayeh BM (2018) Protective effect of vinpocetine against neurotoxicity of manganese in adult male rats. Naunyn-Schmiedeberg’s Arch Pharmacol 391:729–742. https://doi.org/10.1007/s00210-018-1498-0

Article  CAS  Google Scholar 

Gupta S, Singh P, Sharma B, Sharma B (2015) Neuroprotective Effects of Agomelatine and Vinpocetine Against Chronic Cerebral Hypoperfusion Induced Vascular Dementia. CNR 12:240–252. https://doi.org/10.2174/1567202612666150603130235

Article  CAS  PubMed  Google Scholar 

Alkuraishy HM, Al-Gareeb AI, Albuhadilly AK (2014) Vinpocetine and Pyritinol: A New Model for Blood Rheological Modulation in Cerebrovascular Disorders—A Randomized Controlled Clinical Study. Biomed Res Int 2014:1–8. https://doi.org/10.1155/2014/324307

Article  CAS  Google Scholar 

Ishola IO, Akinyede AA, Adeluwa TP, Micah C (2018) Novel action of vinpocetine in the prevention of paraquat-induced parkinsonism in mice: involvement of oxidative stress and neuroinflammation. Metab Brain Dis 33:1493–1500. https://doi.org/10.1007/s11011-018-0256-9

Article  CAS  PubMed  Google Scholar 

Shekarian M, Salehi I, Raoufi S, Asadbegi M, Kourosh-Arami M, Komaki A (2023) Neuroprotective effects of vinpocetine, as a phosphodiesterase 1 inhibitor, on long-term potentiation in a rat model of Alzheimer’s disease. BMC Neurosci 24(1):20

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pereira C, Agostinho P, Oliveira CR (2000) Vinpocetine attenuates the metabolic dysfunction induced by amyloid β-peptides in PC12 cells. Free Radic Res 33(5):497–506

Article  CAS  PubMed  Google Scholar 

Gupta S, Singh P, Mohan Sharma B, Sharma B (2015) Neuroprotective effects of agomelatine and vinpocetine against chronic cerebral hypoperfusion induced vascular dementia. Curr Neurovasc Res 12(3):240–252

Article  CAS  PubMed  Google Scholar 

Ali AA, Abo El-Ella DM, El-Emam SZ et al (2019) Physical & mental activities enhance the neuroprotective effect of vinpocetine & coenzyme Q10 combination against Alzheimer & bone remodeling in rats. Life Sci 229:21–35. https://doi.org/10.1016/j.lfs.2019.05.006

Article  CAS  PubMed  Google Scholar 

Szatmári S, Whitehouse P (2003) Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev 2003(1):CD003119

PubMed  PubMed Central  Google Scholar 

Thal LJ, Salmon DP, Lasker B, Bower D, Klauber MR (1989) The safety and lack of efficacy of vinpocetine in Alzheimer’s disease. J Am Geriatr Soc 37(6):515–520

Article  CAS  PubMed  Google Scholar 

Ogunrin A (2014) Effect of vinpocetine (cognitolTM) on cognitive performances of a nigerian population. Ann Med Health Sci Res 4:654. https://doi.org/10.4103/2141-9248.139368

Article  PubMed  PubMed Central  Google Scholar 

Szatmári S, Whitehouse P (2003) Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev 2010. https://doi.org/10.1002/14651858.cd003119

Sanders O, Rajagopal L (2020) Phosphodiesterase Inhibitors for Alzheimer’s Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale. J Alzheimer’s Disease Rep 4:185–215. https://doi.org/10.3233/adr-200191

Article  Google Scholar 

Zagórska A, Czopek A, Fryc M, Jaromin A, Boyd BJ (2023) Drug discovery and development targeting dementia. Pharmaceuticals 16(2):151

Article  PubMed  PubMed Central  Google Scholar 

Valikovics A, Németh L, Csányi A (2012) Study of the effects of vinpocetin on cognitive functions. Ideggyógyászati szemle 65:115–120